Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112294 · ClinicalTrials.gov registry record · Phase 3
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 755
- Enrollment target
NCT00112294 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 755 participants.
The verdict
NCT00112294, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 755 participants
- Enrollment target
Study Summary
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Interventions
- DRUG Carboplatin
- DRUG Cetuximab
- DRUG Paclitaxel (Taxane)
- DRUG Docetaxel (Taxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112294
The ClinicalTrials.gov registry entry for NCT00112294 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 755 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00112294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112294 about?
NCT00112294 is a clinical study titled "Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer". The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
What is the current status of trial NCT00112294?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 755 participants. The study started on 2004-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00112294?
The interventions under investigation include: Carboplatin (DRUG), Cetuximab (DRUG), Paclitaxel (Taxane) (DRUG), Docetaxel (Taxane) (DRUG).
Who is sponsoring clinical trial NCT00112294?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.